Just when you had written off biotech stocks as boring, here comes the MIT Technology Review to name its “Three technologies ...

The global cell therapy market was valued at $5.88 billion in 2024 and is on track to hit $44.39 billion by 2034, expanding at a striking 22.69% CAGR. Researchers credit this explosive growth to ...

The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments that target genetic diseases at their source([1]) . The FDA approved three ...

Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the best gene-editing stocks to buy according to hedge funds. On November 5, Evercore ISI’s Gavin Clark-Gartner affirmed a Buy rating on Krystal Biotech, ...

The stock has lost significant market value since that debacle. While it's not clear that nex-z was responsible, it's also ...

The ARK Invest founder adds exposure to a speculative biotech play ...

Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 ...

Beam Therapeutics BEAM is engaged in developing investigational gene therapy candidates that are currently in ...

Beam Therapeutics is one of the few biotechs that has shown immense potential in the gene therapy space. The company’s proprietary base-editing technology potentially enables the development of a ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, RBC Capital raised its price target for CRISPR Therapeutics AG (NASDAQ:CRSP ...